Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Liu

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Disease|February 8, 2020
What is synchronous oligometastatic non-small cell lung cancer?Chan-Kyung Jane Cho, Balamurugan A Vellayappan, Emma M Dunne, et al.
Journal of Medical Imaging and Radiation Sciences|May 5, 2019
Template-based Intensity-Modulated Radiation Therapy: A Cost-effective Intensity-Modulated Radiation Therapy Planning Procedure for Prostate CancerFred Cao, Ramani Ramaseshan, Nancy Cooper, et al.
JTO Clinical and Research Reports|May 2, 2022
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief ReportMarie-Hélène Denault, Shelley Kuang, Aria Shokoohi, et al.
Practical Radiation Oncology|September 20, 2024
Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based AnalysisJohn Paul Abrina, Sarah Baker, Ella Mae Cruz-Lim, et al.
American Journal of Clinical Oncology|February 8, 2006
Examining time intervals between diagnosis and treatment in the management of patients with limited stage small cell lung cancerEric Berthelet, Pauline T Truong, Mary Lesperance, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2003
Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapyMitchell Liu, Tom Pickles, Alexander Agranovich, et al.
Frontiers in Oncology|June 14, 2023
Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic diseaseYerim Shin, Jee Suk Chang, Yeseul Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinicShilo Lefresne, Robert Olson, Rosemary Cashman, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 ExpressionMarie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Radiation Oncology (London, England)|May 27, 2026
Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trialsDavid Chen, Ealia Khoshkish, Jane Jomy, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Disease|February 8, 2020
What is synchronous oligometastatic non-small cell lung cancer?Chan-Kyung Jane Cho, Balamurugan A Vellayappan, Emma M Dunne, et al.
Journal of Medical Imaging and Radiation Sciences|May 5, 2019
Template-based Intensity-Modulated Radiation Therapy: A Cost-effective Intensity-Modulated Radiation Therapy Planning Procedure for Prostate CancerFred Cao, Ramani Ramaseshan, Nancy Cooper, et al.
JTO Clinical and Research Reports|May 2, 2022
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief ReportMarie-Hélène Denault, Shelley Kuang, Aria Shokoohi, et al.
Practical Radiation Oncology|September 20, 2024
Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based AnalysisJohn Paul Abrina, Sarah Baker, Ella Mae Cruz-Lim, et al.
American Journal of Clinical Oncology|February 8, 2006
Examining time intervals between diagnosis and treatment in the management of patients with limited stage small cell lung cancerEric Berthelet, Pauline T Truong, Mary Lesperance, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2003
Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapyMitchell Liu, Tom Pickles, Alexander Agranovich, et al.
Frontiers in Oncology|June 14, 2023
Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic diseaseYerim Shin, Jee Suk Chang, Yeseul Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinicShilo Lefresne, Robert Olson, Rosemary Cashman, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 ExpressionMarie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Radiation Oncology (London, England)|May 27, 2026
Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trialsDavid Chen, Ealia Khoshkish, Jane Jomy, et al.
Pageof 10